E-mail

E-mail a Wiley Online Library Link

Giovanni Grignani, Emanuela Palmerini, Silvia Stacchiotti, Antonella Boglione, Virginia Ferraresi, Sergio Frustaci, Alessandro Comandone, Paolo G Casali, Stefano Ferrari and Massimo Aglietta A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β Cancer 117

Version of Record online: 5 OCT 2010 | DOI: 10.1002/cncr.25632

A prospective trial of imatinib mesylate was conducted in patients with nonresectable chondrosarcomas expressing platelet-derived growth factor receptor (PDGFR)-α and PDGFR-β. This targeted therapy does not appear to improve prognosis in patients with chemorefractory disease.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH